Screener
Regenxbio RGNX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Expenses related to at-the-market offering program | (403) | (259) |
| Proceeds from issuance of royalty bond and warrants, net of transaction costs | — | 144,526 |
| Repayments under royalty monetization liabilities, net of interest | (15,181) | (10,854) |
| Net cash provided by financing activities | 3,932 | 133,438 |
| Net increase in cash and cash equivalents and restricted cash | 2,021 | 22,032 |
| Cash and cash equivalents and restricted cash | ||
| Beginning of period | 36,496 | 59,556 |
| End of period | $38,517 | $81,588 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's financing cash flow?
- Regenxbio (RGNX) reported financing cash flow of $17.57M in Q2 2026.
- How has Regenxbio's financing cash flow changed year-over-year?
- Regenxbio's financing cash flow decreased by 87.4% year-over-year, from $139.23M to $17.57M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Regenxbio's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude